Who would qualify under the Canada's Drug Agency recommendation?

Adults with a BMI of 27 kg/m2 or more and prediabetes who have tried at least one diet without success, and who follow a reduced-calorie diet and more physical activity. Renewal after the first year needs at least 5% weight loss from baseline, then yearly review.

Is Zepbound covered by OHIP?

No. OHIP doesn't cover take-home prescriptions, and Ontario's drug benefit formulary listed no tirzepatide product when we checked on October 15, 2026.

Is Zepbound the same as Mounjaro?

Both are tirzepatide made by Eli Lilly. In Canada Mounjaro is authorized for type 2 diabetes and Zepbound for chronic weight management, so plans review them separately.

Does this page recommend a clinic, product or dose?

No. We don't list clinics, sellers, prices or doses, and nothing here is medical advice. Talk to a licensed Canadian prescriber or pharmacist.

Canada \u00b7 Coverage

Is Zepbound covered in Canada? Where coverage stands in 2026.

Zepbound (tirzepatide) has been authorized in Canada for chronic weight management since May 13, 2025. Coverage is the harder question. The short answer: private plans vary, and public plans such as Ontario's don't list it yet, but Canada's Drug Agency gave a narrow positive recommendation in August 2026.

Last reviewed October 15, 2026against Health Canada's Drug Product Database and Canada's Drug Agency and provincial formularies.

The August 2026 recommendation

Canada's Drug Agency (CDA-AMC) issued its final recommendation on August 12, 2026 and published it on August 28. It advises public plans to cover Zepbound only when:

the adult has a BMI of 27 kg/m² or more and prediabetes;
they report at least one unsuccessful diet attempt, and follow a reduced-calorie diet with more physical activity;
the price is reduced;
after the first year, at least 5% weight loss from baseline is documented, with yearly reassessment after that;
it isn't combined with another GLP-1 medicine.

The committee found Zepbound did not show acceptable value for the full weight-management population Health Canada approved, but did for people with prediabetes. There, trials showed sustained weight loss and fewer people progressing to type 2 diabetes.

Public plans today

Plan	Zepbound	Mounjaro (same drug, for diabetes)
Ontario Drug Benefit	Not listed	Not listed (details)
BC PharmaCare	Check the PharmaCare formulary	Non-benefit (details)
Quebec RAMQ	Not covered (weight-loss drugs excluded)	Not listed; INESSS refusal, decision deferred July 2026 (details)
Other provinces	Check your formulary	Check your formulary

Checked October 15, 2026. A CDA-AMC recommendation is advice, not coverage. Provinces usually list a drug only after national price negotiations finish, which can take months.

Private insurance

Employer and individual plans decide for themselves; some cover weight-management drugs, often with prior authorization.
Ask your insurer whether Zepbound is on the drug list and what forms your prescriber must complete.
Compare with Wegovy coverage, the other weekly weight-management injection.

What tirzepatide users report

93 published anonymous tirzepatide confessions; 27 mention at least one side effect.
10 mention Mounjaro or Zepbound by name.
Among confessions that state a weight change in pounds, the median reported is 50 lb. Self-reported, unverified.

Most-mentioned side effects (share of tirzepatide confessions):

Heart rate or palpitations: 11.8% (11)
Anxiety or panic: 5.4% (5)
Burping: 4.3% (4)
Insomnia or poor sleep: 3.2% (3)
Libido: 3.2% (3)

Counts are phrase mentions in anonymous accounts, not diagnoses or clinical rates. Full breakdown and methodology: tirzepatide side-effects report.

By province and city

Ontario · Toronto · Ottawa · Mississauga
Quebec · Montreal
Alberta · Calgary · Edmonton
British Columbia · Vancouver · Kelowna
Manitoba · Winnipeg
Saskatchewan · Saskatoon
Nova Scotia · Halifax
New Brunswick

Frequently asked questions

Is Zepbound covered in Canada?: Generally not by public plans yet: Ontario's drug benefit formulary listed no tirzepatide product on October 15, 2026. Canada's Drug Agency recommended in August 2026 that public plans cover it for a narrow group: adults with a BMI of 27 or more and prediabetes, if the price is reduced. Some private plans already cover it.
Who would qualify under the Canada's Drug Agency recommendation?: Adults with a BMI of 27 kg/m2 or more and prediabetes who have tried at least one diet without success, and who follow a reduced-calorie diet and more physical activity. Renewal after the first year needs at least 5% weight loss from baseline, then yearly review.
Is Zepbound covered by OHIP?: No. OHIP doesn't cover take-home prescriptions, and Ontario's drug benefit formulary listed no tirzepatide product when we checked on October 15, 2026.
Is Zepbound the same as Mounjaro?: Both are tirzepatide made by Eli Lilly. In Canada Mounjaro is authorized for type 2 diabetes and Zepbound for chronic weight management, so plans review them separately.
Does this page recommend a clinic, product or dose?: No. We don't list clinics, sellers, prices or doses, and nothing here is medical advice. Talk to a licensed Canadian prescriber or pharmacist.

Sources

General information only — not medical, legal or regulatory advice. Peptide Confessions does not sell, source or recommend any product or vendor, and nothing here is dosing guidance. Speak with a licensed Canadian healthcare professional or pharmacist about any medication. Editorial process →